|
|
||||||||
Basic Science Investigations |
1 Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, Munich, Germany
2 Nuklearmedizinische Klinik und Poliklinik, Technische Universität München, Munich, Germany
3 Institute of Bioinorganic and Radiopharmaceutical Chemistry, Forschungszentrum Rossendorf, Germany
4 Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York
| ABSTRACT |
|---|
|
|
|---|
Key Words: gene therapy reporter genes VEGF HSV1-tk heart
| INTRODUCTION |
|---|
|
|
|---|
Although the basic methodology has been validated, further studies are needed for translation to applications in cardiac gene therapy. A next step is to coexpress a reporter gene with a therapeutic gene and to demonstrate that therapeutic gene expression can be detected via imaging of reporter gene expression.
We chose the vascular endothelial growth factor (VEGF) gene as the therapeutic gene because it has been applied successfully in trials of clinical gene therapy for treatment of ischemic heart disease (3,4) and because it is considered to be nearing large-scale human application (5). The aim of this study was to evaluate the usefulness of an adenoviral vector coexpressing VEGF and HSV1-tk for noninvasive imaging of cardiac therapeutic gene transfer.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Adenovirus expressing only wild-type HSV1-tk (6), mutant HSV1-sr39tk (kindly provided by Sanjiv S. Gambhir, UCLA) (1), or VEGF (7) were used as controls.
In Vitro Studies
H9c2 rat embryonic cardiac cells were infected as described previously (6). RNA isolation, preparation of cellular extract, and uptake studies were performed 24 h after infection with an increasing multiplicity of infection (MOI). The time course of gene expression was measured at an MOI of 25.
Northern Blot.
RNA was extracted as described previously (8) and was hybridized first with HSV-tk cDNA (1.1 kbp), then with VEGF cDNA (0.45 kbp), and then with 18S-RNA-coding DNA as a loading control. Images were obtained using an FLA-2000 PhosphorImager (Fuji) and quantified with AIDA software (Raytest).
Western Blot.
Infected cells were treated with radioimmunoprecipitation assay buffer and applied to sodium dodecylsulfatepolyacrylamide gel electrophoresis. Western blot was performed according to the standard protocol after incubation of HSV1-tkspecific polyclonal antibody (provided by William Summers, Yale University) and goat antirabbit IgG-peroxidasecoupled secondary antibody (Oncogene Science, Inc.).
Enzyme-Linked Immunosorbent Assay (ELISA).
VEGF secretion into the medium of infected cells was determined using a human VEGF ELISA kit (Oncogene Science, Inc.). For analysis, serum concentration was reduced from 10% to 1% immediately after infection.
Reporter Probe Uptake.
Uptake of reporter probes was measured as previously described (6) and was normalized to the number of viable cells as determined by trypan blue staining. 14C-2'-Fluoro-5-methyl-1-ß-D-arabinofuranosyluracil (FIAU; specific activity 2 GBq/µmol) was obtained commercially (Hartmann Analytic). 9-(4-18F-Fluoro-3-hydroxymethylbutyl)guanine (FHBG) was synthesized according to a protocol developed at Forschungszentrum Rossendorf. Tosylated and methoxytritylated precursor was radiolabeled using a K18F-F/Kryptofix 2.2.2 complex (Merck), followed by splitting off of protection groups under acidic conditions and purification by high-performance liquid chromatography, yielding 18F-FHBG at an average specific activity of 19 GBq/µmol. When indicated, 18F-FHBG was added to incubation medium together with 14C-FIAU. After 1 h of incubation, 18F-FHBG accumulation was measured using a
-counter before addition of tissue solubilizer (Soluene-350; Packard). Scintillation fluid was added 20 h after cell incubation, to allow for decay of 18F. Subsequently, ß-counting was performed as previously described (6).
| RESULTS |
|---|
|
|
|---|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
VEGF gene therapy is currently applied in clinical trials to treat ischemic heart disease, but success in human applications is monitored only indirectly via improvement of symptoms or clinical results such as those of exercise testing or perfusion scintigraphy (3,4). A method that allows for quantitative in vivo visualization of the success of gene transfer and the time course of subsequent transgene expression would be of considerable value. PET performed after coexpression with a reporter gene may not only enhance monitoring of clinical therapeutic gene delivery but also allow linkage of clinical observations and functional test results to transgene expression, thus refining understanding of therapeutic mechanisms. As a next step, a larger animal series will be required to confirm that in vitro correlation between transgenes can be transferred to the in vivo setting.
In several studies on tumor cells, 2 imaging reporter genes have been coexpressed and correlated. Application of equivalent titers of separate adenoviral vectors expressing HSV1-tk or dopamine D2 receptor yielded a good correlation for the uptakes of specific reporter probes (9), but the success of this approach is not guaranteed for infection of all cells with both vectors. Other studies used bicistronic vectors coexpressing both reporter genes linked by internal ribosomal entry site (10). This results in excellent correlation, but the absolute level of expression of the second gene is generally reduced. Finally, the approach of the present studya single vector with 2 expression cassetteshas also been evaluated previously and showed a good correlation between expression of 2 reporter genes (11). To our knowledge, this is the first report on coexpression of a therapeutic gene and a reporter gene for nuclear imaging in cardiac cells.
We evaluated uptake of the pyrimidine derivative FIAU and the acycloguanosine derivative FHBG. Both have been demonstrated to be useful reporter probes for imaging cardiac gene products (1,2). Previous observations are confirmed and extended by demonstration of a relationship between reporter probe uptake and expression of a cotransfected therapeutic gene. More detailed comparison of the 2 probes (and alternative approaches) is beyond the scope of this communication but may be performed in the future to further refine the methodology for imaging cardiac reporter genes.
| CONCLUSION |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
For correspondence or reprints contact: Frank M. Bengel, MD, Nuklearmedizinische Klinik und Poliklinik, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 München, Germany.
E-mail: frank.bengel{at}lrz.tum.de
| REFERENCES |
|---|
|
|
|---|
Related articles in JNM:
This article has been cited by other articles:
![]() |
J. C. Wu, F. M. Bengel, and S. S. Gambhir Cardiovascular Molecular Imaging Radiology, August 1, 2007; 244(2): 337 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wagner, M. Anton, S. G. Nekolla, S. Reder, J. Henke, S. Seidl, R. Hegenloh, M. Miyagawa, R. Haubner, M. Schwaiger, et al. Noninvasive Characterization of Myocardial Molecular Interventions by Integrated Positron Emission Tomography and Computed Tomography J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2107 - 2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miyagawa, M. Anton, R. Haubner, M. V. Simoes, C. Stadele, W. Erhardt, S. Reder, T. Lehner, B. Wagner, S. Noll, et al. PET of Cardiac Transgene Expression: Comparison of 2 Approaches Based on Herpesviral Thymidine Kinase Reporter Gene J. Nucl. Med., November 1, 2004; 45(11): 1917 - 1923. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |